Janux Therapeutics Shares Surge Following Licensing and Development Pact with Bristol Myers Squibb
Janux Therapeutics entered a collaboration and exclusive global licensing agreement with Bristol Myers Squibb to develop an innovative therapeutic targeting a validated antigen found on various solid tumor cancers. This deal includes significant upfront and milestone payments for Janux and assigns Bristol Myers Squibb responsibility for clinical de…